Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2010

Open Access 01-12-2010 | Case report

Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report

Authors: Toshikazu Araoka, Hiroya Takeoka, Keisuke Nishioka, Masaki Ikeda, Makiko Kondo, Azusa Hoshina, Seiji Kishi, Makoto Araki, Rokuro Mimura, Taichi Murakami, Akira Mima, Kojiro Nagai, Hideharu Abe, Toshio Doi

Published in: Journal of Medical Case Reports | Issue 1/2010

Login to get access

Abstract

Introduction

Refractory pleural effusion in systemic immunoglobulin light chain amyloidosis without cardiac decompensation is rarely reported and has a poor prognosis in general (a median survival of 1.6 months). Moreover, the optimum treatment for this condition is still undecided. This is the first report on the successful use of vincristine, adriamycin and dexamethasone chemotherapy for refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis without cardiac decompensation.

Case presentation

We report the case of a 68-year old Japanese male with systemic immunoglobulin light chain amyloidosis presenting with bilateral pleural effusion (more severe on the right side) in the absence of cardiac decompensation that was refractory to diuretic therapy. The patient was admitted for fatigue, exertional dyspnea, and bilateral lower extremity edema. He had been receiving intermittent melphalan and prednisone chemotherapy for seven years. One month before admission, his dyspnea had got worse, and his chest radiograph showed bilateral pleural effusion; the pleural effusion was ascertained to be a transudate. The conventionally used therapeutic measures, including diuretics and thoracocentesis, failed to control pleural effusion. Administration of vincristine, adriamycin, and dexamethasone chemotherapy led to successful resolution of the effusion.

Conclusion

Treatment with vincristine, adriamycin, and dexamethasone chemotherapy was effective for the refractory pleural effusion in systemic immunoglobulin light chain amyloidosis without cardiac decompensation and appears to be associated with improvement in our patient's prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wardley AM, Jayson GC, Goldsmith DJ, Venning MC, Ackrill P, Scarffe JH: The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer. 1998, 78: 774-776.CrossRefPubMedPubMedCentral Wardley AM, Jayson GC, Goldsmith DJ, Venning MC, Ackrill P, Scarffe JH: The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer. 1998, 78: 774-776.CrossRefPubMedPubMedCentral
2.
go back to reference Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM, Falk RH: Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest. 2003, 124: 969-977. 10.1378/chest.124.3.969.CrossRefPubMed Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM, Falk RH: Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest. 2003, 124: 969-977. 10.1378/chest.124.3.969.CrossRefPubMed
3.
go back to reference Maeno T, Sando Y, Tsukagoshi M, Suga T, Endo M, Seki R, Ooyama Y, Yamagishi T, Kaneko Y, Kanda T, Iwasaki T, Kurabayashi M, Nagai R: Pleural amyloidosis in a patient with intractable pleural effusion and multiple myeloma. Respirology. 2000, 5: 79-80. 10.1046/j.1440-1843.2000.00230.x.CrossRefPubMed Maeno T, Sando Y, Tsukagoshi M, Suga T, Endo M, Seki R, Ooyama Y, Yamagishi T, Kaneko Y, Kanda T, Iwasaki T, Kurabayashi M, Nagai R: Pleural amyloidosis in a patient with intractable pleural effusion and multiple myeloma. Respirology. 2000, 5: 79-80. 10.1046/j.1440-1843.2000.00230.x.CrossRefPubMed
4.
go back to reference Pichelmayer O, Zielinski C, Raderer M: Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med. 2005, 353: 740-741. 10.1056/NEJM200508183530722.CrossRefPubMed Pichelmayer O, Zielinski C, Raderer M: Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med. 2005, 353: 740-741. 10.1056/NEJM200508183530722.CrossRefPubMed
5.
go back to reference Hoyer RJ, Leung N, Witzig TE, Lacy MQ: Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am J Hematol. 2007, 82: 409-413. 10.1002/ajh.20858.CrossRefPubMed Hoyer RJ, Leung N, Witzig TE, Lacy MQ: Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am J Hematol. 2007, 82: 409-413. 10.1002/ajh.20858.CrossRefPubMed
6.
go back to reference Ikeda S, Takabayashi Y, Maejima Y, Tachibana N, Ehara T, Nezu A, Hoshii Y: Nodular lung disease with five year survival and unilateral pleural effusion in AL amyloidosis. Amyloid. 1999, 6: 292-296.CrossRefPubMed Ikeda S, Takabayashi Y, Maejima Y, Tachibana N, Ehara T, Nezu A, Hoshii Y: Nodular lung disease with five year survival and unilateral pleural effusion in AL amyloidosis. Amyloid. 1999, 6: 292-296.CrossRefPubMed
7.
go back to reference Migrino RQ, Harmann L, Woods T, Bright M, Truran S, Hari P: Intraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography. Cardiovasc Ultrasound. 2008, 6: 40-10.1186/1476-7120-6-40.CrossRefPubMedPubMedCentral Migrino RQ, Harmann L, Woods T, Bright M, Truran S, Hari P: Intraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography. Cardiovasc Ultrasound. 2008, 6: 40-10.1186/1476-7120-6-40.CrossRefPubMedPubMedCentral
8.
go back to reference Tazawa K, Matsuda M, Yoshida T, Gono T, Katoh N, Shimojima Y, Ishii W, Fushimi T, Koyama J, Ikeda S: Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients. Intern Med. 2008, 47: 1517-1522. 10.2169/internalmedicine.47.0949.CrossRefPubMed Tazawa K, Matsuda M, Yoshida T, Gono T, Katoh N, Shimojima Y, Ishii W, Fushimi T, Koyama J, Ikeda S: Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients. Intern Med. 2008, 47: 1517-1522. 10.2169/internalmedicine.47.0949.CrossRefPubMed
9.
go back to reference Fujimoto N, Masuoka H, Kosaka H, Ota S, Ito M, Nakano T: Primary amyloidosis with pulmonary involvement which presented exudative pleural effusion and high fever. Intern Med. 2003, 42: 756-760. 10.2169/internalmedicine.42.756.CrossRefPubMed Fujimoto N, Masuoka H, Kosaka H, Ota S, Ito M, Nakano T: Primary amyloidosis with pulmonary involvement which presented exudative pleural effusion and high fever. Intern Med. 2003, 42: 756-760. 10.2169/internalmedicine.42.756.CrossRefPubMed
10.
go back to reference Kimlinger T, Kline M, Kumar S, Lust J, Witzig T, Rajkumar SV: Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. Haematologica. 2006, 91: 1033-1040.PubMed Kimlinger T, Kline M, Kumar S, Lust J, Witzig T, Rajkumar SV: Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. Haematologica. 2006, 91: 1033-1040.PubMed
11.
go back to reference Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL: Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007, 139: 224-233. 10.1111/j.1365-2141.2007.06783.x.CrossRefPubMed Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL: Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007, 139: 224-233. 10.1111/j.1365-2141.2007.06783.x.CrossRefPubMed
12.
go back to reference Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007, 109: 492-496. 10.1182/blood-2006-07-030544.CrossRefPubMed Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007, 109: 492-496. 10.1182/blood-2006-07-030544.CrossRefPubMed
13.
go back to reference Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD: Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008, 93: 295-298. 10.3324/haematol.11627.CrossRefPubMed Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD: Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008, 93: 295-298. 10.3324/haematol.11627.CrossRefPubMed
14.
go back to reference Komorowski J, Jerczynska H, Siejka A, Baranska P, Lawnicka H, Pawlowska Z, Stepien H: Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci. 2006, 78: 2558-2563. 10.1016/j.lfs.2005.10.016.CrossRefPubMed Komorowski J, Jerczynska H, Siejka A, Baranska P, Lawnicka H, Pawlowska Z, Stepien H: Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci. 2006, 78: 2558-2563. 10.1016/j.lfs.2005.10.016.CrossRefPubMed
15.
go back to reference Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008, 111: 5291-5297. 10.1182/blood-2007-12-130120.CrossRefPubMedPubMedCentral Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008, 111: 5291-5297. 10.1182/blood-2007-12-130120.CrossRefPubMedPubMedCentral
16.
go back to reference Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006, 66: 184-191. 10.1158/0008-5472.CAN-05-1195.CrossRefPubMed Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006, 66: 184-191. 10.1158/0008-5472.CAN-05-1195.CrossRefPubMed
17.
go back to reference Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004, 125: 681-700. 10.1111/j.1365-2141.2004.04970.x. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol. 2004, 125: 681-700. 10.1111/j.1365-2141.2004.04970.x.
Metadata
Title
Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report
Authors
Toshikazu Araoka
Hiroya Takeoka
Keisuke Nishioka
Masaki Ikeda
Makiko Kondo
Azusa Hoshina
Seiji Kishi
Makoto Araki
Rokuro Mimura
Taichi Murakami
Akira Mima
Kojiro Nagai
Hideharu Abe
Toshio Doi
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2010
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-4-322

Other articles of this Issue 1/2010

Journal of Medical Case Reports 1/2010 Go to the issue